Navigation Links
Stipulation Of Dismissal Of Claims By Plaintiff Cornerstone Biopharma, Inc.
Date:7/11/2013

ESTERO, Fla., July 11, 2013 /PRNewswire/ -- On May 16, 2013, United States District Court for the Eastern District of North Carolina DISMISSED with prejudice all claims for copyright and patent infringement asserted by plaintiffs Cornerstone BioPharma, Inc. ("Cornerstone") and J-Med Pharmaceuticals, Inc. ("J-Med") against Vision Pharma, LLC ("Vision"), Sander Busman, Thomas DeStefano, and Michael McAloose.  The dismissal followed the decision of the United States Court of Appeals for the Federal Circuit, upholding the USPTO Board of Patent Appeals and Interferences' rejection of U.S. Patent No. 6,270,796, the sole patent asserted in the case. See In re J-Med Pharmaceuticals, Inc., No. 11-1415 (Fed. Cir.).  On January 11, 2013, the USPTO issued an Ex Parte Reexamination Certificate cancelling all claims of the '796 Patent.

"We were very confident from the absolute beginning that Vision, Thomas DeStefano, Michael McAloose and I would receive a most favorable outcome regarding Cornerstone and J-Med's case against us.  Although these results are especially pleasing, this decision should not have taken so long to happen," said Sander S. Busman, Founder, President & CEO, Vision Pharma. Vision Pharma was represented by Ben Pleune and David Alban of Alston & Bird, LLP. 

About Vision Pharma

Vision Pharma specializes in niche, generic pharmaceuticals with various delivery options and dosage forms.  The company provides quality products at competitive prices while improving the lives of those who take their medicines. The organization's customer service acts promptly to requests while continuously improving to fulfill each customer and patient need. Maintaining additional inventory ensures Vision's ability to provide increased service levels. The pipeline of generic pharmaceuticals planned to market continues to be a strong focus internally and with other pharmaceutical organizations, domestically and internationally. Valuable relationships that are built show true dedication to each partnering company. You can count on Vision Pharma to consider the patient's safety as a top priority when developing and manufacturing their items. To learn more, please visit www.visionpharma.com.

Media Relations Contact:
Sander S. Busman
Vision Pharma
Founder, President & CEO
sbusman@visionpharma.com

 

 


'/>"/>
SOURCE Vision Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Breckenridge Announces Dismissal of Various Lawsuits Against Macoven Pharmaceuticals in Return for Macovens Discontinuance of Certain Products
2. Medstrat Posts Documents Confirming Terms Of Dismissal Of Merges Lawsuit
3. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intuitive Surgical, Inc. - ISRG
4. Specialty pharmacy utilization management programs and 30-day supply claims may improve patient outcomes, reduce waste
5. Bloomberg BNA Publishes Sixth Edition of False Claims Act Treatise
6. FDA Publicly Challenged to Support Unsubstantiated Claims Regarding Electronic Cigarettes
7. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of MAP Pharmaceuticals, Inc. - MAPP
8. Argus Announces Next Generation Pharmacy Claims Processing Solution
9. American Association for Homecare Expects Medicare to Move Past its Deny-at-All-Costs Culture that Routinely Denies Claims for Power Wheelchairs
10. Abbott Sued for False Claims Related to its Blockbuster Drug TriCor
11. Star Scientific, Inc. Issues Statement in Response to Two Plaintiffs Purported Class Action Law Suits and Multiple Press Releases Issued by Plaintiffs Law Firms Trolling for New Clients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... -- UCB is pleased to announce that 12 scientific abstracts have ... American Epilepsy Society (AES) Annual Meeting, which takes place ... USA. 1-12 Data being presented include ... ® (lacosamide) CV and BRIVIACT ® (brivaracetam) CV. ... state of the union of epilepsy care and antiepileptic drugs ...
(Date:12/2/2016)... -- Allergan plc (NYSE: AGN ), a leading ... announced Accelerated Share Repurchase (ASR) Program. Logo - ... , ... announced, the Company entered into a variable tenor ASR arrangement ... $10 billion of its ordinary shares. Approximately 40.5 million shares ...
(Date:11/30/2016)... , Nov 30, 2016 Research and ... Intracranial Pressure Monitoring Devices 2017 - MedCore" report to their offering. ... , , ... brain and the skull. In healthy individuals, it is circulated though the ... are cases where the amount of CSF surrounding the brain changes significantly. ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... 2016 , ... Center for Autism and Related Disorders (CARD) Portland today announced ... disorder (ASD) and other developmental disabilities. The group, which is being launched with the ... the opportunity to share stories and advice, seek help, and continue their education on ...
(Date:12/2/2016)... ... 2016 , ... U.S. Surgeon General, Dr. Vivek Murthy, graces the cover of ... was inspired to practice medicine at an early age by his father, who was ... diagnoses and prescribing medicine,” he states. “It is about building relationships with people; relationships ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... two ostomy patients, standing as living proof that attitude and determination can combine ... and issues that spike around the holidays. This campaign will offer patients a ...
(Date:12/2/2016)... ... December 02, 2016 , ... More than half of American teens report losing ... report speaking with their child about sex related topics, less than 60 percent spoke ... proud to announce the launch of its second edition of the “Sexual Wellness” campaign, ...
(Date:12/2/2016)... ... 02, 2016 , ... CloudLIMS.com, a class-leading provider of Laboratory ... CloudLIMS Lite helps biobanks, clinical, research and testing laboratories keep track of their ... version is a faster and a more efficient product, allowing batch processing of ...
Breaking Medicine News(10 mins):